Clinical Trials on Hemophilia B, Severe

Total 10345 results

Allergan

Completed

A Safety and Effectiveness Study of JUVÉDERM VOLIFT® XC Versus Control for Moderate to Severe Nasolabial Folds

Moderate to Severe Nasolabial Folds

United States
Kythera Biopharmaceuticals

Completed

Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area

Moderate or Severe Submental Fullness

United States
Kythera Biopharmaceuticals

Completed

Patient Experience Study of Deoxycholic Acid Injection

Moderate or Severe Submental Fullness

United States
Kythera Biopharmaceuticals

Completed

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area (REFINE-1)

Moderate or Severe Submental Fullness

United States, Canada
Assistance Publique Hopitaux De Marseille

Completed

Evaluation of the Effectiveness of a Diagnostic Kit in the Etiological Diagnosis of Fevers of the Traveler

Fevers of the Traveler

France
U.S. Army Medical Research and Development Command

Recruiting

Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever

Viral Hemorrhagic Fever

Germany
International Centre for Diarrhoeal Disease Research...
UNICEF; Nutriset

Completed

Development and Field Testing of Ready-to-use-therapeutic Foods Made of Local Ingredients in Bangladesh for SAM Children

Severe Acute Malnutrition in Childhood

Bangladesh
Beckman Coulter, Inc.

Completed

Evaluation of MDW for Early Detection of Sepsis, Clinical Validity

Sepsis | Severe Sepsis | Severe Infection

France, Spain
Bernhard Nocht Institute for Tropical Medicine

Not yet recruiting

LAssa Fever Adjunct Treatment With DEXamethasone (LADEX)

Lassa Fever
International AIDS Vaccine Initiative
Coalition for Epidemic Preparedness Innovations

Recruiting

A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa

Lassa Fever

Ghana, Liberia, Nigeria
University of Oxford
London School of Hygiene and Tropical Medicine; Public Health England; National... and other collaborators

Terminated

Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Patients With Lassa Fever

Lassa Fever

Sierra Leone
Cukurova University

Completed

The Effects of Exercises on Gait in Hemophilic Individuals

Hemophilic Arthropathy

Turkey
Enzyre B.V.
Indiana Hemophilia & Thrombosis Center

Not yet recruiting

Case and Use Scenario Study to Gain Knowledge on the User Needs for a Medical Device for Hemophilia A Monitoring

Hemophilia A

United States
Hospices Civils de Lyon

Recruiting

EVALUATION OF THE OVERALL HAEMOSTATIC CAPACITY OF MIM8 WITH GLOBAL HAEMOSTASIS ASSAYS AND FIBRIN CLOT ULTRASTRUCTURE (Mim8-TGT)

Hemophilia A

France
Biocad

Recruiting

A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A (EDELWEISS)

Hemophilia A

Russian Federation
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Hemophilia A

Spain, Canada, United States, New Zealand, Italy, Poland
University Hospital, Grenoble

Recruiting

Impact of Emicizumab on Activated Clotting Time Using the i-STAT Alinity Analyzer (EMISTAT)

Hemophilia A

France
Centre Hospitalier Universitaire de Saint Etienne

Recruiting

In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients

Hemophilia

France
World Federation of Hemophilia

Not yet recruiting

The World Federation of Hemophilia Gene Therapy Registry (WFH GTR)

Hemophilia
Prof. Dr. Dr. Thomas Hilberg

Recruiting

Clinical and Health-related Outcome of rFVIIIFc Prophylaxis (CLHEAR)

Hemophilia A

Germany
Brugmann University Hospital

Recruiting

Does the Thrombin Generation Test Performed During the Pharmacokinetic Profile of the Substitutive Factor VIII Bring Benefits to the Personalized Treatment of Pediatric Patients and Adult Hemophilia A Patients Under Prophylaxis ?

Hemophilia

Belgium
Swedish Orphan Biovitrum

Active, not recruiting

A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health (A-MORE)

Hemophilia A

Spain, Germany, Czechia, Italy, Estonia, Finland, Greece, Netherlands, Saudi Arabia, Slovenia, Sweden, Switzerland, United Kingdom
Takeda

Completed

A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.

Hemophilia A

Japan
Takeda
Takeda Pharma Korea Co. Ltd.

Completed

Post Marketing Surveillance Study for ADYNOVATE in South Korea

Hemophilia A

Korea, Republic of
Eli Lilly and Company
Sigilon Therapeutics, Inc.

Terminated

Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A

Hemophilia A

United Kingdom, United States
Baxalta now part of Shire
Takeda Development Center Americas, Inc.

Active, not recruiting

A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

Hemophilia A

Spain, United States, Denmark, Italy, Taiwan, Malaysia, Belgium, Thailand, Turkey, Austria, Bulgaria, Canada, Finland, France, Germany, Hong Kong, Hungary, Korea, Republic of, Netherlands, Norway, Singapore, Ukraine, United Kingdom
Jiangsu Gensciences lnc.

Completed

A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection

Hemophilia A

China
Nantes University Hospital

Completed

Safety and Efficacy in a ReAl-Life Study in Patients With Haemophilia Treated wIth NovoEight® for Surgery (SERAPHINE)

Hemophilia

France
Cliniques universitaires Saint-Luc- Université...

Completed

Outcomes of Prophylaxis With Emicizumab in Children With Severe Hemophilia A in Ivory Coast

Hemophilia A

Côte D'Ivoire
Bioverativ, a Sanofi company

Completed

A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)

Hemophilia A

United States, Japan
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors (HAVEN 2)

Hemophilia A

United States, France, Germany, Italy, South Africa, Spain, Turkey, Japan, United Kingdom, Costa Rica
Baxalta now part of Shire

Completed

BAX 826 Dose-Escalation Safety Study

Hemophilia A

Spain, Bulgaria, Germany, United Kingdom, Italy, Poland, Russian Federation, Netherlands, Hungary
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

BAX 855 PK-guided Dosing (PROPEL)

Hemophilia A

Spain, United States, Australia, Singapore, Taiwan, Hong Kong, Malaysia, Bulgaria, United Kingdom, Switzerland, Ukraine, Turkey, Italy, Norway, France, Austria, Romania, Sweden, Poland, Germany, Hungary, Israel
Baxalta now part of Shire

Completed

Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures

Hemophilia A

United States, Spain, Netherlands, United Kingdom, Bulgaria, Lithuania, Russian Federation, Switzerland, Ukraine
Baxalta now part of Shire
Baxter Innovations GmbH

Terminated

Early Prophylaxis Immunologic Challenge (EPIC) Study (EPIC)

Hemophilia A

Poland, United States, Bulgaria, Serbia, Canada, Russian Federation, Germany, Netherlands, Lithuania, Czechia, Austria, Spain
Baxalta now part of Shire

Completed

Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients

Hemophilia A

United States, France, United Kingdom, Spain, Germany, Canada, Puerto Rico, Italy, Sweden, Austria
Baxalta now part of Shire

Completed

Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A

Hemophilia A

Bulgaria, Russian Federation
Baxalta now part of Shire

Completed

Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

Hemophilia A

United States, Poland, Slovenia, Greece, Russian Federation, Hungary, Italy, United Kingdom, Czechia, Austria
Baxalta now part of Shire

Completed

Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101

Hemophilia A

Canada
Baxalta now part of Shire
Baxter Innovations GmbH

Completed

BAX 855 Dose-Escalation Safety Study

Hemophilia A

Japan, Bulgaria, Germany, United Kingdom
Baxalta now part of Shire

Completed

China ADVATE PTP Study

Hemophilia A

China
Baxalta now part of Shire

Completed

Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A

Hemophilia A

China
Boston VA Research Institute, Inc.
University of Michigan; Emory University; Shire

Withdrawn

Improved Factor VIII Inhibitor Evaluation (IFIE)

Hemophilia A | Hemophilia

United States
The University of Texas Health Science Center,...
Baxter Healthcare Corporation; Rho, Inc.

Completed

Hemophilia Inhibitor Previously Untreated Patient Study (HIPS)

Hemophilia A

United States, Austria, Italy, Netherlands, Sweden
Assistance Publique - Hôpitaux de Paris
Baxter Healthcare Corporation

Terminated

PK Driven Prophylaxis for Hemophilia A (OBTC)

Hemophilia A

France
Catholic University of the Sacred Heart

Unknown

PHYSICAL ACTIVITY AND FVIII CLEARANCE: RELEVANCE FOR PERSONALIZED THERAPY IN SEVERE HAEMOPHILIA A (PHYSEMO) (PHYSEMO)

Hemophilia A

Italy
Sinocelltech Ltd.

Unknown

Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A.

Hemophilia A
Children's Hospital Los Angeles

Completed

Individualizing Hemophilia Prophylaxis Using Thromboelastography

Hemophilia A

United States
Lund University
Shire

Completed

Evaluation of a Standardized Protocol for Thrombin Generation Assay

Hemophilia A

Sweden
Bayer

Completed

Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies (PARkER)

Hemophilia A

United States

Clinical Trials on Hemophilia B, Severe

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations